Stockreport

CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene [Seeking Alpha]

CG Oncology, Inc. - Common stock  (CGON) 
PDF Completion of the rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC and potential FDA acceptance are key near-term catalysts in 2026. Earl [Read more]